In addition, SGLT2 inhibitors may lead to other concerns, including cardiovascular safety, acute renal failure, hypoglycemia, volume depletion, volume depletion, euglycemic ketoacidosis, and bone fractures (Scheen, 2019). This evidence concerns the gene SLC5A2 and acute kidney injury.